AstraZeneca Plc (AZN) announced Tuesday that it's voluntarily delisting its American Depositary Shares and certain guaranteed debt securities from Nasdaq as part of a broader shift to direct stock trading on the New York Stock Exchange.

The transition happens at the end of January 2026. After the market closes on January 30, AstraZeneca's ordinary shares and the affected debt securities will officially move to the NYSE, with trading expected to kick off on February 2. The Nasdaq listings will cease the same day the NYSE trading begins.

This isn't just administrative housekeeping. AstraZeneca is executing a shareholder-approved strategy to simplify its listing structure into what the company calls "a single global framework." Translation: instead of navigating the complexity of American Depositary Receipts, investors will be able to trade the same ordinary shares whether they're in London, Stockholm, or New York.

Once the change takes effect, AstraZeneca ordinary shares will trade across three major exchanges—the London Stock Exchange, Nasdaq Stockholm, and the NYSE. The idea is to make the stock more accessible and attractive to a wider range of global investors.

Michel Demaré, AstraZeneca's Chair, explained the rationale back in September 2025: "Enabling a global listing structure will allow us to reach a broader mix of global investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca's exciting future."

Cancer Drug Advances in Europe

Meanwhile, AstraZeneca got some positive regulatory news on Monday. The European Medicines Agency validated the company's marketing authorization application for Enhertu (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for unresectable or metastatic HER2-positive breast cancer.

Enhertu is a HER2-directed DXd antibody drug conjugate originally discovered by Daiichi Sankyo, which is now jointly developing and commercializing the drug with AstraZeneca.

The validation is a procedural milestone that confirms the application is complete and triggers the scientific review process by the EMA's Committee for Medicinal Products for Human Use.

The application relies on data from the DESTINY-Breast09 phase 3 trial, which was presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine. In that trial, Enhertu combined with pertuzumab showed statistically significant and clinically meaningful improvement in progression-free survival compared to the standard treatment regimen of taxane, trastuzumab, and pertuzumab.

AZN Price Action: AstraZeneca shares were down 3.55% at $91.04 at the time of publication on Tuesday.